Hostname: page-component-6766d58669-6mz5d Total loading time: 0 Render date: 2026-05-19T09:16:57.798Z Has data issue: false hasContentIssue false
  • English
  • Français

Frequent allelic loss at the FRA3B site in endemic nasopharyngeal carcinoma: association with clinical features and Epstein–Barr virus infection

Published online by Cambridge University Press:  15 March 2007

Y F Deng ,
D N Zhou  and
Y D Lu
Y F Deng*
Affiliation:
Department of Otolaryngology, Xiamen, Fujian
D N Zhou
Affiliation:
Department of Pathology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian
Y D Lu
Affiliation:
Department of Otolaryngology, Second Xiangya Hospital, Central South University, Changshan, Hunan, China
*
Address for correspondence: Dr Yan Fei Deng, Department of Otolaryngology, Zhongshan Hospital, Xiamen University, 209 Hubin South Road, Xiamen, Fujian 361004, China. Fax: 86 592 5920902 E-mail: dyanfei@126.com
Get access Rights & Permissions [Opens in a new window]

Abstract

In this study, we aimed to precisely define the patterns of allelic loss at the FRA3B site in endemic nasopharyngeal carcinoma and to determine whether an association exists between allelic loss, clinicopathological features and Epstein–Barr virus infection.

We examined the loss of heterozygosity in 40 cases of nasopharyngeal carcinoma from an endemic area in southern China, using eight high dense, polymorphic, microsatellite markers within or flanking the FRA3B site.

Loss of heterozygosity at the FRA3B region was shown in 31 (77.5 per cent) primary tumours. Loss of heterozygosity was found most frequently at the D3S1300 (55.6 per cent) and D3S2757 (50.0 per cent) loci. The common area of deletion was located between the D3S4103 and D3S4260 loci. In nasopharyngeal carcinoma, loss of heterozygosity at the FRA3B/fragile histidine triad locus correlated with the following clinicopathological parameters: tumour T-stage, lymph node status, clinical stage, tumour differentiation and serum antibody titres of immunoglobulin (Ig) A against Epstein–Barr virus capsid antigen. Significantly frequent loss of heterozygosity was observed in nasopharyngeal carcinoma with tumour stages T3 and T4, lymph node metastasis and advanced tumour–node–metastasis staging (III and IV). Very frequent loss of heterozygosity was also observed to correlate with World Health Organization type III nasopharyngeal carcinoma histopathology. We also found that nasopharyngeal carcinoma patients with high titres of IgA against Epstein–Barr virus capsid antigen showed very frequent loss of heterozygosity.

Allelic loss at the FRA3B site occurs significantly more commonly in endemic nasopharyngeal carcinoma patients. This suggests that the region between D3S4103 and D3S4260 may represent a preferential molecular target in nasopharyngeal carcinogenesis.

Keywords

Nasopharyngeal NeoplasmsCarcinomaChromosome Fragile Sites

Information

Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 121 , Issue 11 , November 2007 , pp. 1073 - 1078
Copyright
Copyright © JLO (1984) Limited 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1Li, X, Wang, E, Zhao, YD, Ren, JQ, Jin, P, Yao, KT et al. Chromosomal imbalances in nasopharyngeal carcinoma: a meta-analysis of comparative genomic hybridization results. J Transl Med 2006;4:1–9CrossRefGoogle ScholarPubMed
2Burgos, JS. Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis. Med Oncol 2005;22:113–21CrossRefGoogle ScholarPubMed
3Chan, AT, Teo, PM, Huang, DP. Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol 2004;31:794–801CrossRefGoogle ScholarPubMed
4Lo, KW, Huang, DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 2002;12:451–62CrossRefGoogle ScholarPubMed
5Becker, NA, Thorland, EC, Denison, SR, Phillips, LA, Smith, DI. Evidence that instability within the FRA3B region extends four megabases. Oncogene 2002;21:8713–22CrossRefGoogle ScholarPubMed
6Fang, JM, Arlt, MF, Buegess, AC, Dagenais, SL, Beer, DG, Glover, TW. Translocation breakpoints in FHIT and FRA3B in both homologs of chromosome 3 in an esophageal adenocarcinoma. Genes Chromosomes Cancer 2001;30:292–83.0.CO;2-F>CrossRefGoogle Scholar
7Corbin, S, Neilly, ME, Espinosa, R 3rd, Davis, EM, McKeithan, TW, Le Beau, MM. Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors. Cancer Res 2002;62:3477–84Google ScholarPubMed
8Kameoka, Y, Tagawa, H, Tsuzuki, S, Karnan, S, Ota, A, Suguro, M et al. Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma. Oncogene 2004;23:9148–54CrossRefGoogle Scholar
9Huebner, K, Croce, CM. Cancer and the FRA3B/FHIT fragile locus: it's a hit. Br J Cancer 2003;88:1501–6CrossRefGoogle Scholar
10Deng, YF, Tian, F, Lu, YD, Chen, ZC, Xie, DH, Yang, XM et al. Mutation and abnormal expression of the fragile histidine triad gene in nasopharyngeal carcinoma. Laryngoscope 2001;111:1589–92CrossRefGoogle ScholarPubMed
11Yuge, T, Nibu, K, Kondo, K, Shibahara, J, Tayama, N, Sugasawa, M. Loss of FHIT expression in squamous cell carcinoma and premalignant lesions of the larynx. Ann Otol Rhinol Laryngol 2005;114:127–31CrossRefGoogle ScholarPubMed
12Thavathiru, E, Ludes-Meyers, JH, Macleod, MC, Aldaz, CM. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR. Mol Carcinog 2005;44:174–82CrossRefGoogle Scholar
13Shao, JY, Zeng, WF, Zeng, YX. Molecular genetic progression on nasopharyngeal carcinoma [in Chinese]. Chin J Cancer 2002;21:1–10Google ScholarPubMed
14Kuroki, T, Tajima, Y, Furui, J, Kanematsu, T. Common fragile genes and digestive tract cancers. Surg Today 2006;36:1–5CrossRefGoogle ScholarPubMed
15Michael, D, Rajewsky, MF. Induction of the common fragile site FRA3B does not affect FHIT expression. Oncogene 2001;20:1798–801CrossRefGoogle Scholar
16Sung, NS, Zeng, Y, Raab-Traub, N. Alterations on chromosome 3 in endemic and nonendemic nasopharyngeal carcinoma. Int J Cancer 2000;86:244–503.0.CO;2-V>CrossRefGoogle ScholarPubMed
17Maniatis, T, Fritsch, EF, Sambrook, J. Molecular Cloning: a Laboratory Manual, 2nd edn.New York: Cold Spring Harbor Laboratory Press, 1989;916–20Google Scholar
18Kuroki, T, Trapasso, F, Yendamuri, S, Matsuyama, A, Alder, H, Mori, M et al. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 2003;63:3724–8Google ScholarPubMed
19Ohta, M, Inoue, H, Cotticelli, MG, Kastury, K, Baffa, R, Palazzo, J et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587–97CrossRefGoogle ScholarPubMed
20Yan, W, Song, L, Wei, W, Li, A, Liu, J, Fang, Y. Chromosomal abnormalities associated with neck nodal metastasis in nasopharyngeal carcinoma. Tumour Biol 2005;26:306–12CrossRefGoogle ScholarPubMed
21Mutirangura, A, Tanunyutthawongese, C, Pornthanakasem, W, Kerekhanjanarong, V, Sriuranpong, V, Yenrudi, S et al. Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. Br J Cancer 1997;76:770–6CrossRefGoogle ScholarPubMed
22Pathmanathan, R, Prasad, U, Sadler, R, Flynn, K, Raab-Traub, N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995;333:693–8CrossRefGoogle ScholarPubMed
23Pegtel, DM, Subramanian, A, Sheen, TS, Tsai, CH, Golub, TR, Thorley-Lawson, DA. Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis. J Virol 2005;79:15430–42CrossRefGoogle ScholarPubMed